Compare Novartis AG (NVS) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Consumer Staples Select Sector SPDR Fund — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Consumer Staples Select Sector SPDR Fund trades at $84.01. The key difference: Novartis AG pays a 3.17% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Novartis AG is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| NVS | XLP | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | — |
52-Week High | $168.62 | $90.00 |
52-Week Low | $113.50 | $75.61 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
XLP trades at $84.86, down 0.39% with a bullish technical signal from moving averages. The ETF shows strong analyst support with a 100% buy rating from 2 analysts and a 2.6% dividend yield. Recent news highlights XLP's defensive positioning amid market volatility, with consumer staples gaining favor as investors seek stability.
The outlook remains positive given XLP's defensive sector exposure and strong technical momentum. Key risks include sector concentration and macroeconomic pressures on consumer spending. With unanimous analyst bullishness and technical indicators supporting further upside, XLP presents a stable equity opportunity in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
